Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
BMJ Open ; 13(4): e068832, 2023 04 20.
Article in English | MEDLINE | ID: mdl-37080616

ABSTRACT

OBJECTIVE: Lung cancer is the most common cause of cancer-related death in the USA. While most patients are diagnosed following symptomatic presentation, no studies have compared symptoms and physical examination signs at or prior to diagnosis from electronic health records (EHRs) in the USA. We aimed to identify symptoms and signs in patients prior to diagnosis in EHR data. DESIGN: Case-control study. SETTING: Ambulatory care clinics at a large tertiary care academic health centre in the USA. PARTICIPANTS, OUTCOMES: We studied 698 primary lung cancer cases in adults diagnosed between 1 January 2012 and 31 December 2019, and 6841 controls matched by age, sex, smoking status and type of clinic. Coded and free-text data from the EHR were extracted from 2 years prior to diagnosis date for cases and index date for controls. Univariate and multivariable conditional logistic regression were used to identify symptoms and signs associated with lung cancer at time of diagnosis, and 1, 3, 6 and 12 months before the diagnosis/index dates. RESULTS: Eleven symptoms and signs recorded during the study period were associated with a significantly higher chance of being a lung cancer case in multivariable analyses. Of these, seven were significantly associated with lung cancer 6 months prior to diagnosis: haemoptysis (OR 3.2, 95% CI 1.9 to 5.3), cough (OR 3.1, 95% CI 2.4 to 4.0), chest crackles or wheeze (OR 3.1, 95% CI 2.3 to 4.1), bone pain (OR 2.7, 95% CI 2.1 to 3.6), back pain (OR 2.5, 95% CI 1.9 to 3.2), weight loss (OR 2.1, 95% CI 1.5 to 2.8) and fatigue (OR 1.6, 95% CI 1.3 to 2.1). CONCLUSIONS: Patients diagnosed with lung cancer appear to have symptoms and signs recorded in the EHR that distinguish them from similar matched patients in ambulatory care, often 6 months or more before diagnosis. These findings suggest opportunities to improve the diagnostic process for lung cancer.


Subject(s)
Electronic Health Records , Lung Neoplasms , Adult , Humans , Case-Control Studies , Tertiary Care Centers , Lung Neoplasms/diagnosis , Ambulatory Care
2.
J Head Trauma Rehabil ; 38(2): 137-146, 2023.
Article in English | MEDLINE | ID: mdl-36883896

ABSTRACT

BACKGROUND: People of color (POC), especially those who also hold social identities associated with disadvantage (non-English-speaking, female, older, lower socioeconomic level), continue to be underserved in the health system, which can result in poorer care and worsened health outcomes. Most disparity research in traumatic brain injury (TBI) focuses on the impact of single factors, which misses the compounding effect of belonging to multiple historically marginalized groups. OBJECTIVE: To examine the intersectional impact of multiple social identities vulnerable to systemic disadvantage following TBI on mortality, opioid usage during acute hospitalization, and discharge location. METHODS: Retrospective observational design utilizing electronic health records merged with local trauma registry data. Patient groups were defined by race and ethnicity (POC or non-Hispanic White), age, sex, type of insurance, and primary language (English-speaking vs non-English-speaking). Latent class analysis (LCA) was performed to identify clusters of systemic disadvantage. Outcome measures were then assessed across latent classes and tested for differences. RESULTS: Over an 8-year period, 10 809 admissions with TBI occurred (37% POC). LCA identified a 4-class model. Groups with more systemic disadvantage had higher rates of mortality. Classes with older populations had lower rates of opioid administration and were less likely to discharge to inpatient rehabilitation following acute care. Sensitivity analyses examining additional indicators of TBI severity demonstrated that the younger group with more systemic disadvantage had more severe TBI. Controlling for more indicators of TBI severity changed statistical significance in mortality for younger groups. CONCLUSION: Results demonstrate significant health inequities in the mortality and access to inpatient rehabilitation following TBI along with higher rates of severe injury in younger patients with more social disadvantages. While many inequities may be related to systemic racism, our findings suggested an additive, deleterious effect for patients who belonged to multiple historically disadvantaged groups. Further research is needed to understand the role of systemic disadvantage for individuals with TBI within the healthcare system.


Subject(s)
Brain Injuries, Traumatic , Intersectional Framework , Humans , Female , Retrospective Studies , Brain Injuries, Traumatic/therapy , Hospitalization , Ethnicity
3.
J Adolesc Health ; 62(2): 176-183, 2018 02.
Article in English | MEDLINE | ID: mdl-29248393

ABSTRACT

PURPOSE: The objectives of this study were to determine whether pediatricians are more likely than other primary care physicians (PCPs) to refer newly diagnosed adolescent and young adult patients with cancer to pediatric oncological specialists, and to assess the physician and patient characteristics that affect patterns of referral. METHODS: A cross-sectional vignette survey was mailed to PCPs to examine hypothetical referral decisions as a function of physician characteristics and patient characteristics, including diagnosis, age, gender, race/ethnicity, family support, transportation, insurance, and patient preference for site of care. Pediatrician PCPs and nonpediatrician PCPs (family medicine, internal medicine, and emergency medicine physicians) practicing in North Carolina and in Washington State participated in the study. RESULTS: A total of 406 surveys were completed (35.8% response rate). Sixty percent of pediatric PCPs referred their hypothetical patients with cancer to pediatric specialists (PSs), compared with only 37% of nonpediatric PCPs. Patient age also influenced referral patterns; 89% of 13-year-olds, 74% of 16-year-olds, 25% of 19-year-olds, and only 9% of 22-year-old patients were referred to a PS. Multivariate logistic regression demonstrated that diagnosis and physician practice setting also were associated with referral patterns. CONCLUSIONS: Both patient age and PCP specialty were significant predictors of referral patterns in hypothetical vignettes of newly diagnosed adolescent and young adult patients with cancer. Pediatricians were more likely than nonpediatrician PCPs to refer patients to a PS. Referrals to PSs decreased dramatically between ages 16 and 19. Because the site of oncological care can impact outcomes, these data have the potential to inform awareness and education initiatives directed at PCPs.


Subject(s)
Decision Making , Neoplasms/therapy , Pediatricians/statistics & numerical data , Physicians, Primary Care/statistics & numerical data , Referral and Consultation/statistics & numerical data , Adolescent , Adult , Age Factors , Cross-Sectional Studies , Female , Health Care Surveys , Humans , Male , Middle Aged , Neoplasms/diagnosis , North Carolina , Specialization , Washington , Young Adult
4.
J Am Board Fam Med ; 29(6): 718-726, 2016 11 12.
Article in English | MEDLINE | ID: mdl-28076255

ABSTRACT

PURPOSE: Problem drug-related behavior (PDB) among patients on chronic opioid therapy may reflect an opioid use disorder. This study assessed PDB prevalence and the relationship between PDB and ongoing prescription of opioids at a primary care clinic that implemented a multifaceted opioid management program. METHODS: A chart review of patients in a chronic opioid registry assessed prevalence of different types of PDB over 2 years, and whether opioids were prescribed during the last 3 months of the 2-year study period among patients with different levels of PDB. RESULTS: Among 233 registry patients, 84.1% exhibited PDB; 45.5% exhibited ≥3 types of PDB. At the end of 2 years, most registry patients were still prescribed opioids, though patients with ≥3 types of PDB were less likely than those without PDB to be prescribed opioids (62.3% vs. 78.4%, P = 0.016). CONCLUSIONS: PDB was pervasive in this population of patients on chronic opioid therapy. Those with the most PDB, and thus with the greatest likelihood of opioid use disorder and its social and medical consequences, were the least likely to be prescribed opioids by the clinic after 2 years. Given the rising rates of illicit opioid use in the U.S., it is important that clinics work closely with their patients who display PDB, systematically assess them for opioid use disorder, and offer evidence-based treatment.


Subject(s)
Analgesics, Opioid/administration & dosage , Analgesics, Opioid/adverse effects , Opioid-Related Disorders/epidemiology , Primary Health Care/statistics & numerical data , Problem Behavior , Adult , Aged , Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Drug Prescriptions/standards , Drug Prescriptions/statistics & numerical data , Evidence-Based Medicine , Female , Humans , Male , Middle Aged , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/psychology , Practice Guidelines as Topic , Prescription Drug Overuse/statistics & numerical data , Prevalence , Primary Health Care/standards , Program Evaluation , Retrospective Studies , United States/epidemiology , Withholding Treatment
5.
Biol Blood Marrow Transplant ; 17(5): 703-9, 2011 May.
Article in English | MEDLINE | ID: mdl-20736078

ABSTRACT

The use of antithymocyte globulin (ATG) in hematopoietic stem cell transplantation (HSCT) conditioning regimens has reduced the incidence of graft-versus-host disease, particularly in its chronic form. The impact of this approach on the prevention of lung dysfunction has not been well characterized, however. We performed a retrospective analysis of pulmonary function in patients who underwent HSCT after conditioning with oral busulfan followed by either cyclophosphamide or fludarabine with or without the addition of ATG. A total of 393 patients were included; 75 patients received ATG, and 318 did not. No differences between the 2 groups were seen in the mean percentage of the predicted values for forced expiratory volume in 1 second (FEV(1)), forced vital capacity (FVC), total lung capacity, and lung CO diffusing capacity at 80 days or 1 year after transplantation. However, the mean value of FEV(1)/FVC ratio at 1 year was higher in the patients who received ATG. The difference in mean change in pulmonary function parameters from baseline to 1 year post-HSCT was statistically nonsignificant for all parameters except FEV(1)/FVC ratio, which demonstrated less decline in the ATG group. The risk of developing severe airflow obstruction or a restrictive pattern was similar in the 2 treatment groups at 1 year post-HSCT. Incorporation of ATG into the HSCT conditioning regimen provided protection against a decline in FEV(1)/FVC ratio but did not decrease the risk of other pulmonary events that we evaluated within the first year after HSCT. Further evaluations in larger numbers of patients are needed to better clarify the role of ATG in the development of delayed pulmonary complications.


Subject(s)
Antilymphocyte Serum/administration & dosage , Immunosuppressive Agents/administration & dosage , Transplantation Conditioning/methods , Administration, Oral , Adult , Animals , Antilymphocyte Serum/immunology , Busulfan/administration & dosage , Busulfan/therapeutic use , Cyclophosphamide/administration & dosage , Female , Forced Expiratory Volume/drug effects , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunosuppressive Agents/immunology , Lung/immunology , Lung/physiopathology , Male , Middle Aged , Myeloablative Agonists/administration & dosage , Myeloablative Agonists/therapeutic use , Pulmonary Diffusing Capacity/drug effects , Rabbits , Retrospective Studies , Time Factors , Transplantation, Homologous , Vidarabine/administration & dosage , Vidarabine/analogs & derivatives , Vital Capacity/drug effects
6.
Biol Blood Marrow Transplant ; 17(7): 1072-8, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21126596

ABSTRACT

Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell transplantation (aHCT). Recent National Institutes of Health consensus diagnostic criteria for BOS have not been assessed in a clinical setting. Modified National Institutes of Health diagnostic consensus criteria for BOS were applied to evaluate its prevalence, risk factors, and outcomes in the modern era of aHCT. Pulmonary function tests from 1145 patients were screened to identify patients with new-onset airflow obstruction. Clinical records were reviewed to exclude pulmonary infection and other causes. The overall prevalence of BOS among all transplanted patients was 5.5%, and 14% among patients with chronic graft-versus-host disease (cGVHD). The median time from transplant to meeting spirometric criteria for BOS was 439 days (range: 274-1690). Although many previously identified risk factors were not significantly associated, lower baseline FEV(1)/FVC ratio (P = .006), non-Caucasian race (P = .014), lower circulating IgG level (P = .010), and presence of cGVHD (P < 0.001) were associated with an increase in risk, with the latter associated with a 10-fold increase in risk. Multivariate analysis indicated that BOS conferred a 1.6-fold increase in risk for mortality after diagnosis. These results suggest that the National Institutes of Health diagnostic criteria can reliably identify BOS, and that it is more prevalent than previously suggested. Spirometric monitoring of high-risk patients with cGVHD may permit earlier detection and intervention for this often-fatal disease.


Subject(s)
Bone Marrow Transplantation/adverse effects , Bronchiolitis Obliterans/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Peripheral Blood Stem Cell Transplantation/adverse effects , Postoperative Complications/epidemiology , Transplantation, Homologous/adverse effects , Adolescent , Adult , Aged , Bronchiolitis Obliterans/diagnosis , Bronchiolitis Obliterans/drug therapy , Bronchiolitis Obliterans/etiology , Bronchiolitis Obliterans/immunology , Busulfan/administration & dosage , Busulfan/adverse effects , Chronic Disease , Early Diagnosis , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/epidemiology , Humans , Immunoglobulin G/blood , Immunosuppressive Agents/therapeutic use , Incidence , Male , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Prevalence , Retrospective Studies , Risk Factors , Spirometry , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , White People , Young Adult
7.
Biol Blood Marrow Transplant ; 16(2): 199-206, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19781655

ABSTRACT

We conducted a 15-year retrospective cohort study to determine the prevalence of restrictive lung disease before allogeneic hematopoietic cell transplantation (HCT), and to assess whether this was a risk factor for poor outcomes. A total of 2545 patients were eligible for the analysis. Restrictive lung disease was defined as a total lung capacity (TLC) < 80% of predicted normal. Chest x-rays and /or computed tomography (CT) scans were reviewed for all restricted patients to determine whether lung parenchymal abnormalities were unlikely or highly likely to cause restriction. Multivariate Cox proportional hazard and sensitivity analyses were performed to assess the relationship between restriction and early respiratory failure and nonrelapse mortality. Restrictive lung disease was present in 194 subjects (7.6%) before HCT. Among these cases, radiographically apparent abnormalities were unlikely to be the cause of the restriction in 149 subjects (77%). In unadjusted and adjusted analyses, the presence of pulmonary restriction was significantly associated with a 2-fold increase in risk for early respiratory failure and nonrelapse mortality, suggesting that these outcomes occurring in the absence of radiographically apparent abnormalities may be related to respiratory muscle weakness. These findings suggest that pulmonary restriction should be considered a risk factor for poor outcomes after transplantation.


Subject(s)
Hematopoietic Stem Cell Transplantation , Lung Diseases, Interstitial/complications , Lung Diseases, Obstructive/complications , Adult , Cohort Studies , Hematopoietic Stem Cell Transplantation/mortality , Humans , Lung Diseases, Interstitial/epidemiology , Lung Diseases, Obstructive/epidemiology , Male , Middle Aged , Prevalence , Respiratory Function Tests , Respiratory Insufficiency/etiology , Retrospective Studies , Risk Factors , Statistics as Topic , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...